Prof. Yehua Shen 沈晔华
Chief Physician, Professor
Medical Oncology (II), Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive treatment of liver, pancreatic, gastrointestinal, gallbladder, and bile duct cancers. Techniques include microwave, cryo, and radiofrequency ablation; arterial infusion chemoembolization; HIFU; and oncolytic virus drug ablation.
Dr. Shen holds an MD from Fudan University Shanghai Medical College and trained under Professor Liu Luming. A former visiting scholar at MD Anderson Cancer Center, Dr. Shen is a Chief Physician and Master’s supervisor at Fudan University Shanghai Cancer Center, performing approximately 800 procedures annually.
Professional roles
- Vice Chair, Tumor Ablation Therapy Committee, Shanghai Anti-Cancer Association
- Member, Pancreatic Disease Committee, Shanghai Association of Integrative Medicine
- Member, Tumor Intervention Committee, Chinese Research Hospital Association
- Member, Traditional Medicine Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Shen Yehua). Papers usually list the name as Yehua Shen or Shen Y.
Selected publications
26 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biol Direct, 2024 (senior author): SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity in pancreatic cancer. PubMed 39183358
- J Thorac Dis, 2023 (senior author): Retrospective cohort study on the correlation analysis among peri-procedural factors, complications, and local tumor progression of lung tumors treated with CT-guided microwave ablation. PubMed 38249890
- Onco Targets Ther, 2020 (senior author): Overexpression of a Long Non-Coding RNA BC037916 is Associated with Pancreatic Tumorigenesis and Poor Prognosis. PubMed 33447050
- Onco Targets Ther, 2020 (first author): miR-939-5p Contributes to the Migration and Invasion of Pancreatic Cancer by Targeting ARHGAP4. PubMed 32021284
- J Cancer Res Ther, 2020 (first author): CSCO ablation expert workshop report: Recommendations for the management of tumor ablation during the coronavirus disease 2019 epidemic. PubMed 32474523
- Carcinogenesis, 2019 (first author): ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. PubMed 30958531
- Onco Targets Ther, 2019 (first author): ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. PubMed 31303760
- Tumour Biol, 2015 (first author): Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. PubMed 25722110
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion